NeuroPace, Inc. revised earnings guidance for the full year 2023. For the year, the company Increased total revenue guidance to range between $59 million and $61 million, representing growth of 30% to 34% over 2022, as compared to prior guidance of between $52 million and $54 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.95 USD | -0.38% | -6.58% | -22.89% |
May. 13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
May. 08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.89% | 230M | |
+11.18% | 227B | |
+15.22% | 198B | |
+19.19% | 142B | |
+30.89% | 111B | |
+1.56% | 64.16B | |
+18.48% | 54.1B | |
+5.12% | 51.41B | |
+10.53% | 45.32B | |
+5.98% | 37.32B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- NeuroPace, Inc. Revises Earnings Guidance for the Full Year 2023